Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Feb;41(2):251–258. doi: 10.1128/aac.41.2.251

Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs.

P D Walzer 1, J Runck 1, P Steele 1, M White 1, M J Linke 1, C L Sidman 1
PMCID: PMC163697  PMID: 9021175

Abstract

Congenitally immunodeficient and immunosuppressed normal mice with naturally acquired Pneumocystis carinii infection were compared as models for testing anti-P. carinii drugs. Among the immunodeficient mice, mice with severe combined immunodeficiency disease (scid), which lack B and T cells, had higher levels of P. carinii pneumonia than did microMT mice, which lack K cells. Normal mice administered dexamethasone in the drinking water had more extensive pneumocystosis than mice administered parenteral methylprednisolone or hybridoma cells making a monoclonal antibody to CD4 cells. The standard anti-P. carinii drugs trimethoprim (TMP)-sulfamethoxazole (SMX), pentamidine, and atovaquone, which work well in rats and humans, worked well in the mice. Clindamycin and primaquine were effective in the scid and microMT mice but not in the immunosuppressed normal mice. High doses of epiroprim, an analog of TMP, appeared to enhance the activities of low doses of SMX and dapsone, while high doses of TMP did not; however, further studies are needed before definitive conclusions about the actions of these drugs can be drawn. Taken together, the data obtained in this study support the growing body of literature suggesting that the mouse is a valid alternative to the rat as a model for testing anti-P. carinii drugs. Additional differences involving the activities of individual drugs in these models will probably emerge as more experience is gained.

Full Text

The Full Text of this article is available as a PDF (1,018.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett M. S., Edlind T. D., Lee C. H., Dean R., Queener S. F., Shaw M. M., Smith J. W. Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice. Antimicrob Agents Chemother. 1994 Aug;38(8):1834–1837. doi: 10.1128/aac.38.8.1834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartlett M. S., Queener S. F., Durkin M. M., Shaw M. A., Smith J. W. Inoculated mouse model of Pneumocystis carinii infection. Diagn Microbiol Infect Dis. 1992 Feb;15(2):129–134. doi: 10.1016/0732-8893(92)90036-s. [DOI] [PubMed] [Google Scholar]
  3. Bartlett M. S., Queener S. F., Shaw M. M., Richardson J. D., Smith J. W. Pneumocystis carinii is resistant to imidazole antifungal agents. Antimicrob Agents Chemother. 1994 Aug;38(8):1859–1861. doi: 10.1128/aac.38.8.1859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bray M. V., Barthold S. W., Sidman C. L., Roths J., Smith A. L. Exacerbation of Pneumocystis carinii pneumonia in immunodeficient (scid) mice by concurrent infection with a pneumovirus. Infect Immun. 1993 Apr;61(4):1586–1588. doi: 10.1128/iai.61.4.1586-1588.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Comley J. C., Sterling A. M. Artificial infections of Pneumocystis carinii in the SCID mouse and their use in the in vivo evaluation of antipneumocystis drugs. J Eukaryot Microbiol. 1994 Nov-Dec;41(6):540–546. doi: 10.1111/j.1550-7408.1994.tb01514.x. [DOI] [PubMed] [Google Scholar]
  6. Comley J. C., Sterling A. M. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. Antimicrob Agents Chemother. 1995 Apr;39(4):806–811. doi: 10.1128/aac.39.4.806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Comley J. C., Yeates C. L., Frend T. J. Antipneumocystis activity of 17C91, a prodrug of atovaquone. Antimicrob Agents Chemother. 1995 Oct;39(10):2217–2219. doi: 10.1128/aac.39.10.2217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fishman J. A., Queener S. F., Roth R. S., Bartlett M. S. Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model. Antimicrob Agents Chemother. 1993 Jul;37(7):1543–1546. doi: 10.1128/aac.37.7.1543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Frenkel J. K., Good J. T., Shultz J. A. Latent Pneumocystis infection of rats, relapse, and chemotherapy. Lab Invest. 1966 Oct;15(10):1559–1577. [PubMed] [Google Scholar]
  10. Greco W. R., Bravo G., Parsons J. C. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995 Jun;47(2):331–385. [PubMed] [Google Scholar]
  11. Hughes W. T., Killmar J. T., Oz H. S. Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model. J Infect Dis. 1994 Oct;170(4):906–911. doi: 10.1093/infdis/170.4.906. [DOI] [PubMed] [Google Scholar]
  12. Hughes W. T., McNabb P. C., Makres T. D., Feldman S. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1974 Mar;5(3):289–293. doi: 10.1128/aac.5.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kim C. K., Foy J. M., Cushion M. T., Stanforth D., Linke M. J., Hendrix H. L., Walzer P. D. Comparison of histologic and quantitative techniques in evaluation of therapy for experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1987 Feb;31(2):197–201. doi: 10.1128/aac.31.2.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kitamura D., Roes J., Kühn R., Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature. 1991 Apr 4;350(6317):423–426. doi: 10.1038/350423a0. [DOI] [PubMed] [Google Scholar]
  15. Marcotte H., Levesque D., Delanay K., Bourgeault A., de la Durantaye R., Brochu S., Lavoie M. C. Pneumocystis carinii infection in transgenic B cell-deficient mice. J Infect Dis. 1996 Apr;173(4):1034–1037. doi: 10.1093/infdis/173.4.1034. [DOI] [PubMed] [Google Scholar]
  16. McFadden D. C., Powles M. A., Smith J. G., Flattery A. M., Bartizal K., Schmatz D. M. Use of anti-CD4+ hybridoma cells to induce Pneumocystis carinii in mice. Infect Immun. 1994 Nov;62(11):4887–4892. doi: 10.1128/iai.62.11.4887-4892.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Powles M. A., McFadden D. C., Pittarelli L. A., Schmatz D. M. Mouse model for Pneumocystis carinii pneumonia that uses natural transmission to initiate infection. Infect Immun. 1992 Apr;60(4):1397–1400. doi: 10.1128/iai.60.4.1397-1400.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Roths J. B., Marshall J. D., Allen R. D., Carlson G. A., Sidman C. L. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. Natural history and pathobiology. Am J Pathol. 1990 May;136(5):1173–1186. [PMC free article] [PubMed] [Google Scholar]
  19. Roths J. B., Sidman C. L. Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice. J Clin Invest. 1992 Aug;90(2):673–678. doi: 10.1172/JCI115910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Roths J. B., Smith A. L., Sidman C. L. Lethal exacerbation of Pneumocystis carinii pneumonia in severe combined immunodeficiency mice after infection by pneumonia virus of mice. J Exp Med. 1993 Apr 1;177(4):1193–1198. doi: 10.1084/jem.177.4.1193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Shellito J., Suzara V. V., Blumenfeld W., Beck J. M., Steger H. J., Ermak T. H. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest. 1990 May;85(5):1686–1693. doi: 10.1172/JCI114621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stringer J. R., Walzer P. D. Molecular biology and epidemiology of Pneumocystis carinii infection in AIDS. AIDS. 1996 Jun;10(6):561–571. doi: 10.1097/00002030-199606000-00001. [DOI] [PubMed] [Google Scholar]
  23. Walzer P. D., Foy J., Runck J., Steele P., White M., Klein R. S., Otter B. A., Sundberg R. J. Guanylhydrazones in therapy of Pneumocystis carinii pneumonia in immunosuppressed rats. Antimicrob Agents Chemother. 1994 Nov;38(11):2572–2576. doi: 10.1128/aac.38.11.2572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Walzer P. D., Foy J., Steele P., Kim C. K., White M., Klein R. S., Otter B. A., Allegra C. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1992 Sep;36(9):1935–1942. doi: 10.1128/aac.36.9.1935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Walzer P. D., Foy J., Steele P., White M. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. Antimicrob Agents Chemother. 1993 Jul;37(7):1436–1443. doi: 10.1128/aac.37.7.1436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Walzer P. D., Foy J., Steele P., White M. Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. Antimicrob Agents Chemother. 1992 Sep;36(9):1943–1950. doi: 10.1128/aac.36.9.1943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Walzer P. D., Kim C. K., Foy J. M., Linke M. J., Cushion M. T. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1988 Jan;32(1):96–103. doi: 10.1128/aac.32.1.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Walzer P. D., Kim C. K., Linke M. J., Pogue C. L., Huerkamp M. J., Chrisp C. E., Lerro A. V., Wixson S. K., Hall E., Shultz L. D. Outbreaks of Pneumocystis carinii pneumonia in colonies of immunodeficient mice. Infect Immun. 1989 Jan;57(1):62–70. doi: 10.1128/iai.57.1.62-70.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Walzer P. D., LaBine M., Redington T. J., Cushion M. T. Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumocystis carinii pneumonia. J Immunol. 1984 Nov;133(5):2502–2508. [PubMed] [Google Scholar]
  30. Walzer P. D., Powell R. D., Jr, Yoneda K. Experimental Pneumocystis carinii pneumonia in different strains of cortisonized mice. Infect Immun. 1979 Jun;24(3):939–947. doi: 10.1128/iai.24.3.939-947.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Walzer P. D., Powell R. D., Jr, Yoneda K., Rutledge M. E., Milder J. E. Growth characteristics and pathogenesis of experimental Pneumocystis carinii pneumonia. Infect Immun. 1980 Mar;27(3):928–937. doi: 10.1128/iai.27.3.928-937.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Walzer P. D., Runck J., Orr S., Foy J., Steele P., White M. Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies. Antimicrob Agents Chemother. 1997 Feb;41(2):242–250. doi: 10.1128/aac.41.2.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Walzer P. D., Rutledge M. E. Serum antibody responses to Pneumocystis carinii among different strains of normal and athymic mice. Infect Immun. 1982 Feb;35(2):620–626. doi: 10.1128/iai.35.2.620-626.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Walzer P. D., Rutledge M. E., Yoneda K. Experimental Pneumocystis carinii pneumonia in C3H/HeJ and C3HeB/FeJ mice. J Reticuloendothel Soc. 1983 Jan;33(1):1–9. [PubMed] [Google Scholar]
  35. Walzer P. D., Schnelle V., Armstrong D., Rosen P. P. Nude mouse: a new experimental model for Pneumocystis carinii infection. Science. 1977 Jul 8;197(4299):177–179. doi: 10.1126/science.301657. [DOI] [PubMed] [Google Scholar]
  36. Yasuoka A., Oka S., Komuro K., Shimizu H., Kitada K., Nakamura Y., Shibahara S., Takeuchi T., Kondo S., Shimada K. Successful treatment of Pneumocystis carinii Pneumonia in mice with benanomicin A (ME1451). Antimicrob Agents Chemother. 1995 Mar;39(3):720–724. doi: 10.1128/AAC.39.3.720. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES